Results 191 to 200 of about 21,302 (228)
Some of the next articles are maybe not open access.
Drug and Therapeutics Bulletin, 2020
Abstract Review of: Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents.
openaire +2 more sources
Abstract Review of: Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents.
openaire +2 more sources
A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage
Journal of Intensive Care Medicine, 2020Purpose: Current guidelines favor 4F-PCC over plasma for reversal of warfarin. Uncertainty remains on the hemostatic effectiveness and thrombotic risk of 4F-PCC for direct-acting oral anticoagulants (DOACs), particularly in patients with intracranial ...
K. Berger +3 more
semanticscholar +1 more source
Gender-Associated Variation in DOAC Levels
Clinical Laboratory, 2023Direct oral anticoagulants (DOAC) such as Xa inhibitors rivaroxaban (riva) and apixaban (apix) are increasingly replacing Vitamin K antagonists in prophylaxis and treatment of venous thromboembolism (VTE). Measurements of DOAC plasma levels may be necessary in certain clinical conditions to determine the further dosage.
Anja, Moldenhauer +3 more
openaire +2 more sources
DOAC dosing in renal impairment
Drug and Therapeutics Bulletin, 2019Dabigatran was the first direct acting oral anticoagulant (DOAC) launched in the UK and has been in clinical use for over 10 years. Since then, ▾rivaroxaban, apixaban and ▾edoxaban have been marketed, and between them the four DOACs account for over 800 000 prescriptions per month in England.1 DOACs provide some advantages over warfarin, including a ...
openaire +2 more sources
Thrombosis Research, 2019
The recent approval of direct-acting oral anticoagulants (DOAC) for long-term anticoagulation in atrial fibrillation and venous thromboembolism resulted in a rapid implementation of these new drugs into daily care. Although DOAC dosing is similar for women and men and, overall, results in comparable outcomes, sex specific issues need to be considered ...
openaire +3 more sources
The recent approval of direct-acting oral anticoagulants (DOAC) for long-term anticoagulation in atrial fibrillation and venous thromboembolism resulted in a rapid implementation of these new drugs into daily care. Although DOAC dosing is similar for women and men and, overall, results in comparable outcomes, sex specific issues need to be considered ...
openaire +3 more sources
DOAC prescribing in people with renal impairment
Drug and Therapeutics Bulletin, 2023Abstract Overview of: Joy M, Williams J, Emanuel S, et al. Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014–2019). Heart 2022. doi: 10.1136/heartjnl-2022-321377. [Epub ahead of print 9 Sept 2022].
openaire +2 more sources
Pharmacokinetics and Pharmacodynamics of DOAC
2021Direct oral anticoagulants (DOACs) have become available as an alternative to warfarin anticoagulation in non-valvular atrial fibrillation. The DOACs, dabigatran (a reversible direct thrombin inhibitor) and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban offer fixed dosing, more predictable pharmacokinetics and fewer interactions ...
openaire +1 more source
Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples
International Journal of Laboratory Hematology, 2020Directs oral anticoagulants (DOACs) can interfere with coagulation assays, especially in thrombophilia workup. To avoid these interferences, a new device, DOAC Filter, allows the removal of DOACs from citrated plasma. This study aims to confirm that DOAC
P. Sevenet +6 more
semanticscholar +1 more source
DOAC’s in de huisartsenpraktijk
Praktische Huisartsgeneeskunde, 2017Het NHG heeft recent een nieuw standpunt anticoagulantia gepubliceerd waarin geen voorkeur meer is voor de cumarinederivaten. DOAC’s worden sindsdien ook vergoed op recept van de huisarts, wat een aantal verwijzingen naar de specialist overbodig zal maken. Wat zijn voor- en nadelen en (contra)indicaties?
openaire +1 more source
Filtering Out Use of DOACs in Hemodialysis
Annals of Pharmacotherapy, 2017Published data exploring the best approach to initiating and maintaining anticoagulation in the setting of renal support therapy are scarce, as these patients were excluded in clinical trials. When developing an anticoagulation regimen in this setting, it is important to assess thrombosis risk, identify the unique drivers for thrombosis and bleeding ...
William E, Dager, Jin A, Lee
openaire +2 more sources